(Q37968025)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22166409%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

The serotonin system: a potential target for anti-dyskinetic treatments and biomarker discovery (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22166409%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

0 references

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22166409%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Daniella Rylander

series ordinal

1

1 reference

26 August 2017

1 January 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22166409%20AND%20SRC:MED&resulttype=core&format=json

Parkinsonism and Related Disorders

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22166409%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

18 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22166409%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

S126-8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22166409%20AND%20SRC:MED&resulttype=core&format=json

New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970039-6

7 January 2021

5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970039-6

7 January 2021

Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970039-6

7 January 2021

Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970039-6

7 January 2021

L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970039-6

7 January 2021

Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970039-6

7 January 2021

Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970039-6

7 January 2021

L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970039-6

7 January 2021

Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970039-6

7 January 2021

Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970039-6

7 January 2021

Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970039-6

7 January 2021

Serotonin induces long-term depression at corticostriatal synapses

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970039-6

7 January 2021

Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970039-6

7 January 2021

Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970039-6

7 January 2021

Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970039-6

7 January 2021

Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970039-6

7 January 2021

Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970039-6

7 January 2021

Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970039-6

7 January 2021

Neural grafting in Parkinson's disease unraveling the mechanisms underlying graft-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970039-6

7 January 2021

Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2811%2970039-6

7 January 2021

10.1016/S1353-8020(11)70039-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22166409%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference